1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

IPF marketers push for more patients

 
• By Lisa LaMotta

With both Esbriet and Ofev gaining approval on the same day, Roche's Genentech and Boehringer Ingelheim have been working to differentiate their respective drugs in the idiopathic pulmonary fibrosis market. Recent spates of data released at the American Thoracic Society annual meeting in Denver could help expand the patient populations for the two therapies.

Both Roche's Esbriet (pirfenidone) and Boehringer's Ofev (nintedanib) were approved by FDA on 15 October and the companies have said the drugs are off to a strong start (Roche...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.